Location via proxy:   [ UP ]  
[Report a bug]   [Manage cookies]                
Jump to content

Idursulfase: Difference between revisions

Browse history interactively
Page 1
Page 2
← Previous edit
Content deleted Content added
VisualWikitext
Script assisted update of identifiers for the Chem/Drugbox validation project (updated: 'ChEMBL').
wording
 
(20 intermediate revisions by 17 users not shown)
Line 1: Line 1:
{{Drugbox
{{Drugbox
| Verifiedfields = changed
| Verifiedfields = changed
| verifiedrevid = 413661956
| verifiedrevid = 458433866
| IUPAC_name =
| IUPAC_name =
| image =
| image =
⚫
<!-- Clinical data -->

⚫
<!--Clinical data-->
| tradename =
| tradename =
| Drugs.com = {{drugs.com|monograph|idursulfase}}
| Drugs.com = {{drugs.com|monograph|idursulfase}}
Line 11: Line 10:
| pregnancy_US = <!-- A / B / C / D / X -->
| pregnancy_US = <!-- A / B / C / D / X -->
| pregnancy_category =
| pregnancy_category =
| licence_EU = yes
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
| legal_CA = <!-- / Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_CA = <!-- / Schedule I, II, III, IV, V, VI, VII, VIII -->
Line 17: Line 17:
| legal_status =
| legal_status =
| routes_of_administration =
| routes_of_administration =
⚫
<!-- Pharmacokinetic data -->

⚫
<!--Pharmacokinetic data-->
| bioavailability =
| bioavailability =
| protein_bound =
| protein_bound =
Line 24: Line 23:
| elimination_half-life =
| elimination_half-life =
| excretion =
| excretion =
⚫
<!-- Identifiers -->

⚫
<!--Identifiers-->
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = NA
| ChemSpiderID = none
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 50936-59-9
| CAS_number = 50936-59-9
Line 33: Line 31:
| ATC_suffix = AB09
| ATC_suffix = AB09
| PubChem =
| PubChem =
| DrugBank_Ref = {{drugbankcite|changed|drugbank}}
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB01271
| DrugBank = DB01271
| UNII_Ref = {{fdacite|changed|FDA}}
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 5W8JGG2651
| UNII = 5W8JGG2651
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D04499
| KEGG = D04499
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = <!-- blanked - oldvalue: 1201826 -->
| ChEMBL = 1201826
<!-- Chemical data -->
| chemical_formula =
| chemical_formula =

| molecular_weight =
| molecular_weight =
}}
}}
'''Idursulfase''' (brand name '''Elaprase''') is a drug used to treat [[Hunter syndrome]] (also called [[Mucopolysaccharoidosis]] II).<ref name="pmid17459751">{{cite journal |author=Garcia AR, DaCosta JM, Pan J, Muenzer J, Lamsa JC |title=Preclinical dose ranging studies for enzyme replacement therapy with idursulfase in a knock-out mouse model of MPS II |journal=Mol. Genet. Metab. |volume=91 |issue=2 |pages=183–90 |year=2007 |pmid=17459751 |doi=10.1016/j.ymgme.2007.03.003}}</ref> It is a purified form of the [[lysosome|lysosomal]] [[enzyme]] [[iduronate-2-sulfatase]] and is produced by [[recombinant DNA technology]] in a human cell line.
'''Idursulfase''' (brand name '''Elaprase'''), manufactured by [[Takeda Pharmaceutical Company|Takeda]], is a drug used to treat [[Hunter syndrome]] (also called [[Mucopolysaccharoidosis#MPS II|MPS-II]]).<ref name="pmid17459751">{{cite journal |vauthors=Garcia AR, DaCosta JM, Pan J, Muenzer J, Lamsa JC |title=Preclinical dose ranging studies for enzyme replacement therapy with idursulfase in a knock-out mouse model of MPS II |journal=Mol. Genet. Metab. |volume=91 |issue=2 |pages=183–90 |year=2007 |pmid=17459751 |doi=10.1016/j.ymgme.2007.03.003}}</ref> It is a purified form of [[iduronate-2-sulfatase]], a [[lysosome|lysosomal]] enzyme, and is produced by [[recombinant DNA technology]] in a human cell line.

⚫
It is one of the most expensive drugs ever produced, costing $375,000 per year.<ref>{{cite news |url=http://www.mediadoctor.ca/content/article.jsp?intArticleID=293 |title=Drug approved to treat rare but potentially deadly disease |accessdate=2011-04-29 |format= |work=}}</ref><ref>[http://www.forbes.com/2010/02/19/expensive-drugs-cost-business-healthcare-rare-diseases_print.html Health Care: The World's Most Expensive Drugs], Matthew Herper, Forbes, Feb. 22, 2010</ref>


⚫
It is one of the most expensive drugs ever produced, costing US$567,412 per patient per year.<ref>{{cite news |url=http://www.mediadoctor.ca/content/article.jsp?intArticleID=293 |title=Drug approved to treat rare but potentially deadly disease |access-date=2011-04-29 |archive-url=https://web.archive.org/web/20110224123252/http://www.mediadoctor.ca/content/article.jsp?intArticleID=293 |archive-date=2011-02-24 |url-status=dead }}</ref><ref>[https://www.forbes.com/2010/02/19/expensive-drugs-cost-business-healthcare-rare-diseases_print.html Health Care: The World's Most Expensive Drugs], Matthew Herper, Forbes, Feb. 22, 2010</ref><ref>[http://www.marketwatch.com/story/1bn-here-we-come-martin-shkreli-told-turing-board-as-daraprim-buy-got-closer-2016-02-03?dist=countdown], Barbara Kollmeyer, Marketwatch, Fed. 3, 2016</ref>
It is manufactured by [[Shire Pharmaceuticals Group]].


==References==
==References==
Line 58: Line 54:


{{Other alimentary tract and metabolism products}}
{{Other alimentary tract and metabolism products}}

[[Category:Orphan drugs]]
[[Category:Orphan drugs]]
[[Category:Drugs developed by Takeda Pharmaceutical Company]]




{{gastrointestinal-drug-stub}}
{{gastrointestinal-drug-stub}}

[[de:Iduronat-2-Sulfatase]]
[[it:Idursulfase]]
[[nl:Idursulfase]]
[[ja:イデュルスルファーゼ]]
[[sv:Idursulfas]]
Retrieved from "https://en.wikipedia.org/wiki/Special:ComparePages"